Raxibacumab Biosimilar Monoclonal Antibody (Anthrax Protective Antigen) for Research
Anti-anthrax protective antigen (PA) [Bacillus anthracis] therapeutic antibody (Pre-made Raxibacumab biosimilar, Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Raxibacumab [1] is a human monoclonal antibody intended for the prophylaxis and treatment of inhaled anthrax. Its efficacy has been proven in rabbits and monkeys.[2] In December 212 raxibacumab was approved in the United States for the treatment of inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs, and for prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate.[3][4]
Order Information
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-968-1mg | 1mg | 618 |
| GMP-Bios-INN-968-10mg | 10mg | |
| GMP-Bios-INN-968-100mg | 100mg | |
| GMP-Bios-INN-968-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Raxibacumab Biosimilar, Whole Mab: Anti-Anthrax Protective Antigen (Pa) [Bacillus Anthracis] therapeutic antibody |
| INN Name | Raxibacumab |
| Target | anthrax protective antigen (PA) [Bacillus anthracis] |
| Format | Whole mAb |
| Derivation | human |
| Species Reactivity | human |
| CH1 Isotype | IgG1 - lambda |
| VD LC | IgG1 - lambda |
| Highest_Clin_Trial (Jan '20) | |
| Est. Status | |
| 100% SI Structure | |
| 99% SI Structure | |
| 95-98% SI Structure | |
| Year Proposed | |
| Year Recommended | |
| Companies | GlaxoSmithKline (Brentford UK) / Human Genome Sciences Inc. (HGSI) (Rockville MD USA) |
| Conditions Approved | |
| Conditions Active | |
| Conditions Discontinued | |
| Development Tech | Cambridge Antibody Technology (CAT) human antibody phage display library |

